Clinical trials: Esophagogastric Junction
Esophageal Cancer, Gastroesophageal Junction Cancer
Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer
Sorafenib is a drug being studied for the treatment of cancer. Sorafenib has been shown to block certain proteins on the surface of some cancer cells called "growth factor receptors." Blocking these growth factor receptors can…
- Trial name
- NCT00917462
- Testing
- Sorafenib, administered orally, CT/MRI
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Adenocarcinoma Esophagus
Circulating Tumor DNA (ctDNA) in Locally Advanced Esophageal and Gastroesophageal (GE) Junction Adenocarcinoma
This is an observational study to determine the feasibility of assessing tumor response utilizing ctDNA in patients of locally advanced esophageal and gastroesophageal junction (LA-EA/GEJ) cancer undergoing total neoadjuvant…
- Trial name
- TRACT DNA (NCT05067842)
- Testing
- Circulating tumor DNA(ctDNA) level measurement
- Where
- United States
- Sponsor
- Medical College of Wisconsin
HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen
This study will assess the efficacy and safety of SHR-A1811 compared with treatment chosen by the investigator in participants with HER2-positive (defined as immunohistochemistry [IHC] 3+ or IHC 2+/in situ hybridization [ISH]+)…
- Trial name
- NCT06123494
- Testing
- SHR-A1811, Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Adenocarcinoma of the Gastroesophageal Junction, Gastric Cancer
Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer
RATIONALE: Drugs used in chemotherapy, such as epirubicin hydrochloride, cisplatin, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from…
- Trial name
- NCT01123473
- Testing
- capecitabine, cisplatin, epirubicin hydrochloride
- Where
- 4 sites in Belgium, Germany and 1 more
- Volunteers
- 29 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Gastroesophageal Junction (GEJ) Adenocarcinoma
An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma
This study is to evaluate the effectiveness of treatment for esophagogastric junction carcinoma, total neoadjuvant therapy (TNT) including pembrolizumab and FLOT is conducted, aiming to choose between surgery or organ…
- Trial name
- NCT07018570
- Testing
- Pembrolizumab, Docetaxel, Oxaliplatin
- Where
- Japan
- Volunteers
- 26 people
- Sponsor
- National Cancer Center Hospital East
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Emotional Distress and Pathologic Response in Locally Advanced Gastric/GEJ Adenocarcinoma
This is a single-center, prospective observational cohort study designed to evaluate the association between pretreatment emotional distress and pathologic response to perioperative immunotherapy in patients with locally advanced…
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Emotional Distress, Pathologic Response
- Trial name
- NCT07662070
- Testing
- Not applicable- observational study
- Volunteers
- 120 people
- Sponsor
- West China Second University Hospital
Siewert Type II Adenocarcinoma of Esophagogastric Junction
Comparison of Different Operations for Siewert Type II Adenocarcinoma of Esophagogastric Junction
The incidence of esophagogastric junction has been increasing in recent years, and surgery is an important method for the treatment of adenoma at the esophagogastric junction.
- Trial name
- NCT05356520
- Testing
- Endoscopy Ivor-lewis, Laparoscopic transabdominal enlarged gastrectomy
- Where
- China
- Volunteers
- 212 people
- Sponsor
- Xijing Hospital of Digestive Diseases
Gastric Cancer, Pancreatic Cancer
Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression
This is an open label, multi-center, Phase 1 clinical trial to evaluate the safety and efficacy of autologous claudin18.2 chimeric antigen receptor T-cell therapy in advanced solid tumors with positive CLDN18.2 expression
- Conditions
- Gastric Cancer, Pancreatic Cancer, Advanced Ovarian Carcinoma, Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT05472857
- Testing
- Claudin 18.2 CAR-T
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Suzhou Immunofoco Biotechnology Co., Ltd
Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8
National Cancer Institute "Cancer Moonshot Biobank"
This trial collects multiple tissue and blood samples, along with medical information, from cancer patients. The "Cancer Moonshot Biobank" is a longitudinal study.
- Conditions
- Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8
- Trial name
- NCT04314401
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 150 sites in United States, Puerto Rico
- Volunteers
- 1,600 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma - Gastroesophageal Junction (GEJ), Gastric Adenocarcinoma
Sequential FDG-PET and miRNA as Biomarkers of Preoperative Treatment Strategy in LA Oesophago-Gastric Cancer
GastroPET is a prospective, multicenter, non-randomized interventional study evaluating sequential FDG-PET as an early biomarker to guide preoperative treatment in patients with locally advanced resectable oesophago-gastric…
- Conditions
- Adenocarcinoma - Gastroesophageal Junction (GEJ), Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
- Trial name
- GastroPET (NCT07791329)
- Testing
- FDG-PET
- Where
- Czechia
- Volunteers
- 144 people
- Sponsor
- Masaryk Memorial Cancer Institute
Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
Neoadjuvant SHR-A1811 ± Adebrelimab in GC/GEJ
This single-center, dual-cohort, exploratory phase II trial evaluates the efficacy and safety of trastuzumab rezetecan (SHR-A1811), an anti-HER2 antibody-drug conjugate (ADC), with or without the anti-PD-L1 antibody adebrelimab…
- Trial name
- NCT07912957
- Testing
- Trastuzumab Rezetecan (SHR-A1811), Trastuzumab Rezetecan (SHR-A1811) + Adebrelimab
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Fudan University
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer
The main purpose of this study is to evaluate the efficacy of an alternative dose of ramucirumab in combination with paclitaxel in participants with second-line metastatic or locally advanced, unresectable gastric or…
- Trial name
- NCT02514551
- Testing
- Ramucirumab, Paclitaxel
- Where
- 52 sites in United States, Belgium and 9 more
- Volunteers
- 245 people
- Sponsor
- Eli Lilly and Company
HER 2 Positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AUR103 Calcium in Patients With HER2-positive Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
The study will have a dose escalation part (Phase 1b) and a randomized part (Phase 2). In Phase 1b, patients diagnosed with advanced HER2 positive gastric/gastroesophageal adenocarcinoma will be enrolled in a 3 + 3 design dose…
- Trial name
- NCT07040059
- Testing
- AUR103 Calcium, Trastuzumab + CAPOX (Capecitabine + Oxaliplatin)
- Where
- 8 sites in India
- Volunteers
- 2 people
- Sponsor
- Aurigene Discovery Technologies Limited
Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8
Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery
This phase II/III trial studies the usefulness of treatment with nivolumab and ipilimumab in addition to standard of care chemotherapy and radiation therapy in patients with esophageal and gastroesophageal junction adenocarcinoma…
- Conditions
- Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8
- Trial name
- NCT03604991
- Testing
- Biospecimen Collection, Carboplatin, Computed Tomography
- Where
- 488 sites in United States
- Volunteers
- 278 people
- Sponsor
- National Cancer Institute (NCI)
Gastric Adenocarcinoma, Adenocarcinoma of Gastroesophageal Junction
A Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer
This trial is a multicenter, randomized, controlled clinical study to evaluate the efficacy and safety of Docetaxel for Injection (Albumin-bound) and Taxotere in locally advanced or metastatic gastric adenocarcinoma or…
- Trial name
- NCT05705635
- Testing
- Docetaxel for injection (Albumin-bound), Taxotere
- Where
- China
- Volunteers
- 100 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Proximal Gastric Adenocarcinoma, Adenocarcinoma of Esophagogastric Junction
A Modified Esophagogastric Reconstruction Method After Laparoscopic Proximal Gastrectomy
The double-flap technique (DFT) is an effective digestive tract reconstruction method after proximal gastrectomy (PG) to reduce the incidence of postoperative reflux esophagitis.
- Conditions
- Proximal Gastric Adenocarcinoma, Adenocarcinoma of Esophagogastric Junction, Anastomosis
- Trial name
- NCT05829213
- Testing
- "arch-bridge-type" esophagogastric reconstruction after proximal gastrectomy
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University
Esophageal Cancer, Esophageal Adenocarcinoma
TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer
Despite treatment according to the CROSS-regimen, median overall survival is less than four years (2.3 QALYs). The burden of disease is within the highest category (0.71 to 1.0).
- Trial name
- TRAP-2 (NCT05188313)
- Testing
- Trastuzumab, Pertuzumab, Paclitaxel
- Where
- Netherlands
- Volunteers
- 376 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Gastric Adenocarcinoma, Esophagogastric Junction Adenocarcinoma
Sintilimab Combined With Chemotherapy as Adjuvant Treatment for Phase III GC and GEJ
This study is a prospective, single-arm, phase II clinical study. Screening patients with stage III GC/GEJ adenocarcinoma after D2 or broader radical resection.
- Trial name
- NCT06761846
- Testing
- Sintilimab plus Chemotherapy
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction
C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer
This partially randomized phase I/II trial studies the side effects and best dose of c-Met inhibitor AMG 337 when given together with oxaliplatin, leucovorin calcium, and fluorouracil and to see how well they work in treating…
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Gastrointestinal Cancer
- Trial name
- NCT02344810
- Testing
- c-Met inhibitor AMG 337, oxaliplatin, leucovorin calcium
- Where
- United States
- Sponsor
- Eastern Cooperative Oncology Group
Esophageal Cancer, Gastric Cancer
Docetaxel and Irinotecan in Treating Patients With Advanced Cancer of the Esophagus or Stomach
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of combining docetaxel and irinotecan in treating patients…
- Trial name
- NCT00004235
- Testing
- docetaxel, irinotecan hydrochloride
- Where
- 19 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- Alliance for Clinical Trials in Oncology
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.